Novavax Moving Forward with COVID-19 Vaccine FDA Submission
Results from the PREVENT-19 trial show the vaccine yields a 90% efficacy rate against symptomatic disease.
Related Articles
Budesonide Maintains IgA Nephropathy Kidney Failure Reduction, Quality of Life at 2 Years
New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.
GPT-4 Nears “Expert-Level” Performance in Ophthalmology Examination
Modern large language models perform strongly on ophthalmic knowledge assessments and approach or exceed the scores of fully qualified and trainee ophthalmologists.
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to…
JOIN | APAC
The Academy of Physician Associates consists of Physician Associates at all levels of their professional careers, ranging from PA students to clinically practicing PA’ s,…
FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA
The FDA approved ustekinumab-aekn for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Latest Conference Articles
The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Visual Impairment Associated with Heightened Risk of Suicidal Tendencies
Vision issues were linked to an increased risk of suicidal ideation, suicidal behavior, and suicide death, particularly among adolescents.
Electronic Health Record-Based Population Health Management Strategy May Improve CKD Care
Although the intervention did not reduce risk of CKD progression versus standard care, it addressed barriers to care and increased patients’ exposure to ACEi/ARBs.
Insight on the Promising 52-Week KarXT Data with Rishi Kakar, MD
In an interview with HCPLive, Rishi Kakar, MD, discussed the positive long-term xanomeline-trospium data from EMERGENT-4.
Tirzepatide Shows Benefit in Obstructive Sleep Apnea, SURMOUNT-OSA Trial
Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission…